ADHD medication

...

Amanda Greenwood

By Amanda Greenwood

Associate News Editor

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


Millions of Americans who rely on medication to manage Attention‑Deficit Hyperactivity Disorder (ADHD) could face continuing difficulties with their prescriptions, as a prolonged shortage of key stimulant drugs stretches into another year.

According to research by JAMA Health Forum, cited by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota, shortages of ADHD medications—including widely prescribed stimulants such as amphetamine‑based and methylphenidate‑based drugs—highlight deeper structural weaknesses in the U.S. pharmaceutical supply chain.

A Fragile Global Supply Chain

Many of the active pharmaceutical ingredients needed to produce ADHD medications are sourced overseas. The CIDRAP report links ongoing shortages to global supply chain disruptions that began during the COVID‑19 pandemic and have not fully resolved.

Read More on News

Manufacturing slowdowns have made it difficult for manufacturers to rapidly increase supply when disruptions occur. As the CIDRAP reports, “Sharp, simultaneous production cutbacks across several medium-sized and smaller manufacturers in late 2022 and early 2023 coincided with a steep contraction in U.S. imports of raw amphetamines and more modest declines in phenylacetone.”

At the same time, the report notes that the U.S. drug supply chain lacks resilience, meaning there are few backup manufacturers or alternative sources when problems arise.

According to a study reported by CIDRAP, “33.7 percent of generic APIs [active pharmaceutical ingredients] for the U.S. market in 2020 and 2021 were produced by a single facility, and another 30.4 percent by only two or three facilities.”

As a result, even temporary production issues can lead to nationwide shortages that persist for months.

Regulatory and Manufacturing Limits

Compounding the problem are federal production caps on stimulant medications. ADHD drugs classified as controlled substances are subject to manufacturing quotas set by the Drug Enforcement Administration (DEA), which limits how much of each drug can be produced annually.

While these quotas are designed to prevent diversion and misuse, multiple experts have warned that they may not easily adjust to sudden increases in legitimate medical demand.

Demand Has Risen Sharply

Demand for ADHD medications has grown in recent years, driven in part by increased awareness and diagnosis of the condition among both children and adults. Telehealth expansion during the pandemic made it easier for patients to access evaluations and treatment, further increasing prescription rates.

However, supply has not kept pace with this growth.

Implications for Patients

According to the CDC, for patients, the consequences are significant. Interrupted access to ADHD medication can impair concentration, academic performance, and job productivity, while also worsening anxiety and depression.

Some patients may be forced to switch medications, reduce doses, or go without treatment altogether.

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines